Mary E. Taplin, MD

Publications

• Shinagare AB, Fennessy FM, Ramaiya NH, Jagannathan JP, Taplin ME, Van den Abbeele AD.Urothelial cancers of the upper urinary tract: metastatic pattern and its correlation with tumor histopathology and location.J Comput Assist Tomogr.;35(2):217-22.
  21412093
• Wu Y, Rosenberg JE, Taplin ME.Novel agents and new therapeutics in castration-resistant prostate cancer.Curr Opin Oncol. 2011 Feb 9.
  21311328
• Shinagare AB, Ramaiya NH, Jagannathan JP, Fennessy FM, Taplin ME, Van den Abbeele AD.Metastatic pattern of bladder cancer: correlation with the characteristics of the primary tumor.AJR Am J Roentgenol. 2011 Jan;196(1):117-22.
  21178055
• Nakabayashi M, Oh WK, Jacobus S, Regan MM, Taplin ME, Kantoff PW, Rosenberg JE.Activity of ketoconazole after taxane-based chemotherapy in castration-resistant prostate cancer.BJU Int. 2010 May;105(10):1392-6.
  19863532
• Scher HI, Beer TM, Higano CS, Anand A, Taplin ME, Efstathiou E, Rathkopf D, Shelkey J, Yu EY, Alumkal J, Hung D, Hirmand M, Seely L, Morris MJ, Danila DC, Humm J, Larson S, Fleisher M, Sawyers CL, .Antitumour activity of MDV3100 in castration-resistant p
  20398925
• Danila DC, Morris MJ, de Bono JS, Ryan CJ, Denmeade SR, Smith MR, Taplin ME, Bubley GJ, Kheoh T, Haqq C, Molina A, Anand A, Koscuiszka M, Larson SM, Schwartz LH, Fleisher M, Scher HI.Phase II Multicenter Study of Abiraterone Acetate Plus Prednisone Therap
  20159814
• Taplin ME, Regan MM, Ko YJ, Bubley GJ, Duggan SE, Werner L, Beer TM, Ryan CW, Mathew P, Tu SM, Denmeade SR, Oh WK, Sartor O, Mantzoros CS, Rittmaster R, Kantoff PW, Balk SP.Phase II study of androgen synthesis inhibition with ketoconazole, hydrocortisone,
  19887483
• Sartor O, Nakabayashi M, Taplin ME, Ross RW, Kantoff PW, Balk SP, Oh WK.Activity of dutasteride plus ketoconazole in castration-refractory prostate cancer after progression on ketoconazole alone.Clin Genitourin Cancer. 2009 Oct;7(3):E90-2.
  19815488
• Choueiri TK,Xie W,D'Amico AV,Ross RW,Hu JC,Pomerantz M,Regan MM,Taplin ME,Kantoff PW,Sartor O,Oh WK.Time to prostate-specific antigen nadir independently predicts overall survival in patients who have metastatic hormone-sensitive prostate cancer treat
  19152438
• Taplin ME.Androgen receptor: role and novel therapeutic prospects in prostate cancer.Expert Rev Anticancer Ther. 2008 Sep;8(9):1495-508. Review.
  18759700
• Taplin ME, Manola J, Oh WK, Kantoff PW, Bubley GJ, Smith M, Barb D, Mantzoros C, Gelmann EP, Balk SP.A phase II study of mifepristone (RU-486) in castration-resistant prostate cancer, with a correlative assessment of androgen-related hormones.BJU Int. 200
  18399827
• Ross RW, Xie W, Regan MM, Pomerantz M, Nakabayashi M, Daskivich TJ, Sartor O, Taplin ME, Kantoff PW, Oh WK.Efficacy of androgen deprivation therapy (ADT) in patients with advanced prostate cancer: association between Gleason score, prostate-specific antig
  18293426
• Ross RW, Oh WK, Xie W, Pomerantz M, Nakabayashi M, Sartor O, Taplin ME, Regan MM, Kantoff PW, Freedman M.Inherited variation in the androgen pathway is associated with the efficacy of androgen-deprivation therapy in men with prostate cancer.J Clin Oncol.
  18281655
• Nakabayashi M, Sartor O, Jacobus S, Regan MM, McKearn D, Ross RW, Kantoff PW, Taplin ME, Oh WK.Response to docetaxel/carboplatin-based chemotherapy as first- and second-line therapy in patients with metastatic hormone-refractory prostate cancer.BJU Int. 2
  18184327
• Ross RW, Beer TM, Jacobus S, Bubley GJ, Taplin ME, Ryan CW, Huang J, Oh WK.A phase 2 study of carboplatin plus docetaxel in men with metastatic hormone-refractory prostate cancer who are refractory to docetaxel.Cancer. 2008 Feb 1;112(3):521-6.
  18085595
• Pomerantz M, Manola J, Taplin ME, Bubley G, Inman M, Lowell J, Beard C, Kantoff PW, Oh WK.Phase II study of low dose and high dose conjugated estrogen for androgen independent prostate cancer.J Urol. 2007 Jun;177(6):2146-50.
  17509304
• Taplin ME.Drug insight: role of the androgen receptor in the development and progression of prostate cancer.Nat Clin Pract Oncol. 2007 Apr;4(4):236-44. Review.
  17392714
• Taplin ME, Xie W, Bubley GJ, Ernstoff MS, Walsh W, Morganstern DE, Regan MM.Docetaxel, estramustine, and 15-month androgen deprivation for men with prostate-specific antigen progression after definitive local therapy for prostate cancer.J Clin Oncol. 2006
  17135641
• Taplin ME.Biochemical (Prostate-Specific Antigen) Relapse: An Oncologist's Perspective.Rev Urol. 2003;5 Suppl 2:S3-S13.
  16986044
• , Berry DL, Moinpour CM, Jiang CS, Ankerst DP, Petrylak DP, Vinson LV, Lara PN, Jones S, Taplin ME, Burch PA, Hussain MH, Crawford ED.Quality of life and pain in advanced stage prostate cancer: results of a Southwest Oncology Group randomized trial compar
  16782921
• Petrylak DP, Ankerst DP, Jiang CS, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99-16.J Natl
  16622120
• Ross RW, Halabi S, Ou SS, Rajeshkumar BR, Woda BA, Vogelzang NJ, Small EJ, Taplin ME, Kantoff PW,.Predictors of prostate cancer tissue acquisition by an undirected core bone marrow biopsy in metastatic castration-resistant prostate cancer--a Cancer and Le
  16299243
• Nakabayashi M, Regan MM, Lifsey D, Kantoff PW, Taplin ME, Sartor O, Oh WK.Efficacy of nilutamide as secondary hormonal therapy in androgen-independent prostate cancer.BJU Int. 2005 Oct;96(6):783-6.
  16153200
• Taplin ME, George DJ, Halabi S, Sanford B, Febbo PG, Hennessy KT, Mihos CG, Vogelzang NJ, Small EJ, Kantoff PW.Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group
  16098367
• Petrylak DP, Tangen CM, Hussain MH, Lara PN, Jones JA, Taplin ME, Burch PA, Berry D, Moinpour C, Kohli M, Benson MC, Small EJ, Raghavan D, Crawford ED.Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate ca
  15470214
• Mobley JA, Lam YW, Lau KM, Pais VM, L'Esperance JO, Steadman B, Fuster LM, Blute RD, Taplin ME, Ho SM.Monitoring the serological proteome: the latest modality in prostate cancer detection.J Urol. 2004 Jul;172(1):331-7.
  15201806
• Loblaw DA, Mendelson DS, Talcott JA, Virgo KS, Somerfield MR, Ben-Josef E, Middleton R, Porterfield H, Sharp SA, Smith TJ, Taplin ME, Vogelzang NJ, Wade JL, Bennett CL, Scher HI.American Society of Clinical Oncology recommendations for the initial hormona
  15184404
• Taplin ME, Balk SP.Androgen receptor: a key molecule in the progression of prostate cancer to hormone independence.J Cell Biochem. 2004 Feb 15;91(3):483-90.
  14755679
• Chun NS, Savani B, Seder RH, Taplin ME.Acute renal failure after intravenous anti-D immune globulin in an adult with immune thrombocytopenic purpura.Am J Hematol. 2003 Dec;74(4):276-9.
  14635210
• Taplin ME, Kantoff PW.The ingredients for prostate cancer nomograms: the addition of biomarkers sets the table for future recipes.J Clin Oncol. 2003 Oct 1;21(19):3552-3.
  12913104
• Taplin ME, Rajeshkumar B, Halabi S, Werner CP, Woda BA, Picus J, Stadler W, Hayes DF, Kantoff PW, Vogelzang NJ, Small EJ,.Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663.J Clin Oncol. 2003 Jul 15
  12860943
• Taplin ME, Bubley GJ, Rajeshkumar B, Shuster T, Ko YJ, Morganstern DE.Docetaxel, estramustine, and short-term androgen withdrawal for patients with biochemical failure after definitive local therapy for prostate cancer.Semin Oncol. 2001 Aug;28(4 Suppl 15)
  11685726
• Taplin ME, Ho SM.Clinical review 134: The endocrinology of prostate cancer.J Clin Endocrinol Metab. 2001 Aug;86(8):3467-77.
  11502765
• Leav I, Lau KM, Adams JY, McNeal JE, Taplin ME, Wang J, Singh H, Ho SM.Comparative studies of the estrogen receptors beta and alpha and the androgen receptor in normal human prostate glands, dysplasia, and in primary and metastatic carcinoma.Am J Pathol.
  11438457
• Savarese DM, Halabi S, Hars V, Akerley WL, Taplin ME, Godley PA, Hussain A, Small EJ, Vogelzang NJ.Phase II study of docetaxel, estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: a final report of CALGB 9780. Cancer
  11331330
• Savarese D, Taplin ME, Halabi S, Hars V, Kreis W, Vogelzang N.A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of cancer and leukemia group B Trial 9780
  10604268
• Taplin ME, Bubley GJ, Ko YJ, Small EJ, Upton M, Rajeshkumar B, Balk SP.Selection for androgen receptor mutations in prostate cancers treated with androgen antagonist.Cancer Res. 1999 Jun 1;59(11):2511-5.
  10363963
• Fenton MA, Shuster TD, Fertig AM, Taplin ME, Kolvenbag G, Bubley GJ, Balk SP.Functional characterization of mutant androgen receptors from androgen-independent prostate cancer.Clin Cancer Res. 1997 Aug;3(8):1383-8.
  9815822
• Joyce R, Fenton MA, Rode P, Constantine M, Gaynes L, Kolvenbag G, DeWolf W, Balk S, Taplin ME, Bubley GJ.High dose bicalutamide for androgen independent prostate cancer: effect of prior hormonal therapy.J Urol. 1998 Jan;159(1):149-53.
  9400459
• Taplin ME, Frantz ME, Canning C, Ritz J, Blumberg RS, Balk SP.Evidence against T-cell development in the adult human intestinal mucosa based upon lack of terminal deoxynucleotidyltransferase expression.Immunology. 1996 Mar;87(3):402-7.
  8778025
• Taplin ME, Bubley GJ, Shuster TD, Frantz ME, Spooner AE, Ogata GK, Keer HN, Balk SP.Mutation of the androgen-receptor gene in metastatic androgen-independent prostate cancer.N Engl J Med. 1995 May 25;332(21):1393-8.
  7723794